3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
29
Fallopian Tube Neoplasms
15
Breast Neoplasms
10
Carcinoma, Ovarian Epithelial
6
Peritoneal Neoplasms
3
Multiple Myeloma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasms
2
Neoplasm Metastasis
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, Large B-Cell, Diffuse
2
Vaccinia
1
Uterine Cervical Neoplasms
1
Sarcoma, Kaposi
1
Pelvic Neoplasms
1
Neoplasms, Plasma Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Low Grade Serous Ovarian Cancer
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Genital Neoplasms, Female
1
Genetic Predisposition to Disease
1
Endometrial Neoplasms
1
Carcinoma
1
Acquired Immunodeficiency Syndrome
1
AIDS-related Kaposi sarcoma
1
Interventions
Cisplatin
53
Paclitaxel
27
Carboplatin
22
Brachytherapy
18
Radiotherapy
17
human papillomavirus vaccine, L1 type 16, 18
12
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
12
Gemcitabine
12
Topotecan
8
Vaccines, Synthetic
7
Platinum
7
Papillomavirus Vaccines
7
Radiation
6
Bevacizumab
6
1,2-diaminocyclohexaneplatinum II citrate
6
Neoadjuvant Therapy
5
Chemotherapy, Adjuvant
5
pembrolizumab
4
Vinorelbine
4
Radiotherapy, Intensity-Modulated
4
Pemetrexed
4
Drug Therapy
4
Taxes
3
Surgical Procedures, Operative
3
Ondansetron
3
Irinotecan
3
Dexamethasone
3
Chemoradiotherapy
3
tisotumab vedotin
2
specific substance maruyama
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Uterine Cervical Neoplasms
×
liposomal doxorubicin
×
Clear all
NCT02584478
2023-11-08
AL3818
Advenchen Laboratories, LLC
Phase 3
Unknown
294 enrolled